8WTI image
Entry Detail
PDB ID:
8WTI
Keywords:
VIRAL PROTEIN
Title:
Crystal structure of the SARS-CoV-2 main protease in complex with 20j
Biological Source:
Source Organism:
Severe acute respiratory syndrome coronavirus 2
Host Organism:
Escherichia coli
PDB Version:
Deposition Date:
2023-10-18
Release Date:
2024-08-28
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.50 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 1 21 1
8WTI validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:3C-like proteinase nsp5
Chain IDs:A, B
Chain Length:306
Number of Molecules:2
Biological Source:Severe acute respiratory syndrome coronavirus 2
UniProt ID:P0DTD1 Pfam ID:PF05409 EC:2.7.7.48
Ligand Molecules
PEG
SO4
X1Z
Primary Citation
Discovery of alpha-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups.
Bioorg.Chem. 143 107001 107001 (2024)
PMID: 38101266 DOI: 10.1016/j.bioorg.2023.107001

Abstact

Although the SARS-CoV-2 pandemic has ended, multiple sporadic cases still exist, posing a request for more antivirals. The main protease (Mpro) of SARS-CoV-2, a key enzyme for viral replication, is an attractive target for drug development. Here, we report the discovery of a new potent α-ketoamide-containing Mpro inhibitor, N-((R)-1-cyclohexyl-2-(((R)-3-methoxy-1-oxo-1-((1-(2-oxo-2-((thiazol-2-ylmethyl)amino)acetyl)cyclobutyl)amino)propan-2-yl)amino)-2-oxoethyl)-4,4-difluorocyclohexane-1-carboxamide (20j). This compound presented promising enzymatic inhibitory activity against SARS-CoV-2 Mpro with an IC50 value of 19.0 nM, and an excellent antiviral activity in cell-based assay with an EC50 value of 138.1 nM. This novel covalent inhibitor may be used as a lead compound for subsequent drug discovery against SARS-CoV-2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
8WTI